PRMEHIGH SIGNALFINANCIAL10-K

PRME shows severe cash burn with cash dropping 65.5% to $63M while operating losses increased 32.3% to -$162.6M, creating potential liquidity concerns for this biotech company.

The dramatic cash decline combined with accelerating losses suggests PRME may need additional financing within the next 12-18 months to sustain operations. While revenue grew 55%, the absolute amount ($4.6M) remains minimal relative to the substantial operating losses, indicating the company is still in early development stages with significant funding needs ahead.

Comparing 2026-03-03 vs 2025-02-28View on EDGAR →
FINANCIAL ANALYSIS

PRME's financial position deteriorated significantly with cash falling from $182.5M to $63M while operating cash flow worsened to -$162.6M, suggesting potential near-term financing needs. Total liabilities surged 53.7% to $221.9M and stockholders' equity declined 21.1%, though total assets still grew 15.2% likely due to R&D investments or acquisitions. Despite 55% revenue growth to $4.6M, the minimal revenue base cannot offset the substantial cash burn rate, signaling this biotech remains heavily dependent on external financing to fund its Prime Editing technology development.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
-65.5%
$182.5M→$63.0M

Cash declined 65.5% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Revenue
P&L
+55.3%
$3.0M→$4.6M

Strong top-line growth of 55.3% — accelerating demand or successful expansion into new markets.

Total Liabilities
Balance Sheet
+53.7%
$144.4M→$221.9M

Liabilities grew 53.7% — significant increase in debt or obligations, assess impact on financial flexibility.

Capital Expenditure
Cash Flow
-37.9%
$7.3M→$4.5M

Capex reduced 37.9% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Operating Cash Flow
Cash Flow
-32.3%
-$122.9M→-$162.6M

Operating cash flow fell 32.3% — earnings quality concerns; investigate working capital changes and non-cash items.

Stockholders Equity
Balance Sheet
-21.1%
$153.1M→$120.9M

Equity decreased 21.1% — buybacks or losses reducing book value, monitor solvency ratios.

Total Assets
Balance Sheet
+15.2%
$297.5M→$342.7M

Asset base grew 15.2% — expansion through organic growth, acquisitions, or capital deployment.

Current Assets
Balance Sheet
-14.4%
$211.9M→$181.3M

Current assets declined 14.4% — monitor working capital adequacy and short-term liquidity.

LANGUAGE CHANGES
NEW — 2026-03-03
PRIOR — 2025-02-28
ADDED
As of February 20, 2026, there were 180,552,179 shares of Common Stock, $0.00001 par value per share, outstanding.
Food and Drug Administration, or FDA, based on the data from our Phase 1/2 trial of PM359 for the treatment of chronic granulomatous disease, or CGD, and the outcomes of any such interactions; our ability to maintain an effective system of internal controls; the effect of unfavorable macroeconomic conditions or market volatility resulting from national or global economic conditions or geopolitical developments, including high inflation and capital market disruptions, iii changes in or disruptions of U.S.
The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of important factors, including those described in the sections titled Summary of the Material Risks Associated with Our Business and Risk Factors.
Business Overview We are a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression.
Our approach is grounded in Prime Editing, a next-generation gene editing technology that enables targeted modifications to genomic DNA without introducing double-stranded breaks.
+7 more — sign up free →
REMOVED
As of February 20, 2025, there were 131,160,842 shares of Common Stock, $0.00001 par value per share, outstanding.
The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of important factors, including those described in the sections titled Summary Risk Factors and Risk Factors.
Business Overview We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies.
We are deploying Prime Editing technology, which we believe is a versatile, precise, and efficient gene editing technology.
The field of genetic medicine has rapidly evolved over the last decade, with groundbreaking advances in gene therapy, cell therapy, ribonucleic acid, or RNA, therapy, and, more recently, gene editing.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →